Trends in Inflation-Adjusted Pharmacotherapy Costs and Cardiovascular Risk Factor Management in Type 2 Diabetes: A 26-Year Study from Tertiary Diabetes Centres in Greece
Experimental and Clinical Endocrinology & Diabetes · 2026-11-05
DOI: 10.1055/a-2978-1630 ↗Abstract
Abstract We evaluated long-term trends in pharmacotherapy costs and cardiovascular risk factor target achievement among people with type 2 diabetes attending tertiary diabetes centres in Greece. This periodic, multicenter, cross-sectional study analysed data from 4,963 people with type 2 diabetes attending three diabetes centres at specific time points: 1998, 2006, 2012, 2018, and 2024. We compared glycated haemoglobin, systolic blood pressure, low-density lipoprotein cholesterol, and body mass index and the achievement of individual cardiovascular risk factor targets (glycated haemoglobin: < 7%, systolic blood pressure: < 140 mm Hg, and low-density lipoprotein cholesterol: < 100 mg/dL) and all three targets simultaneously. Annual pharmacotherapy costs were compared using inflation-adjusted values. Simultaneous achievement of all three cardiovascular risk factor targets increased from 0.6% in 1998 to 29.1% in 2024. Individual target achievements improved: glycated haemoglobin from 29.4 to 58.6%, systolic blood pressure from 45.3 to 62.5%, and low-density lipoprotein cholesterol from 6.3 to 73.4%. Mean low-density lipoprotein cholesterol showed the greatest reduction from 128.4 to 79.0 mg/dL. Median body mass index increased until 2018 and then declined in 2024. Total pharmacotherapy costs per patient rose from €341 in 1998 to €1,609 in 2024, primarily due to glucose-lowering therapies (€167–€1,257). Over 26 years, people with type 2 diabetes attending tertiary diabetes centres in Greece demonstrated improvements in cardiovascular risk factor target achievement, alongside rising pharmacotherapy costs, primarily driven by glucose-lowering therapies.
EUVIMED